利拉鲁肽联合二甲双胍在2型糖尿病并发冠心病临床治疗中的应用优势

Advantages of Liraglutide Combined with Metformin in the Clinical Treatment of Type 2 Diabetes Mellitus Complicated by Coronary Artery Disease

目的通过给予2型糖尿病并发冠状动脉粥样硬化性心脏病(简称冠心病)患者利拉鲁肽联合二甲双胍治疗方式,探讨联合用药的临床效果及优势。方法选取2021年1月—2022年12月菏泽市定陶区中医医院收治的60例糖尿病并发冠心病患者作为研究对象,采用信封法进行分组,每组30例,在规范使用冠心病药物同时对照组实施单一二甲双胍治疗,观察组实施利拉鲁肽联合二甲双胍治疗,对比疗效。结果相较于对照组,治疗后观察组各时间节点血糖水平、心功能指标水平、药物不良反应发生率以及生活质量评分均有显著优势,差异有统计学意义(P<0.05)。结论给予糖尿病并发冠心病患者利拉鲁肽联合二甲双胍治疗方案,能够显著改善血糖水平以及心功能;同时用药期间未发生药物相关不良反应,且生活质量较治疗前有显著提升。

Objective To explore the clinical effects and advantages of combined medication by giving type 2 diabetes complicated with coronary heart is coronary Atherosclerosis heart disease(coronary heart disease for short)patients Liraglutide combined with Metformin as a treatment modality.Methods From January 2021 to December 2022,60 patients with diabetes complicated with coronary heart disease who were admitted to Dingtao District Hospital of Traditional Chinese Medicine in Heze City were selected as the research objects.They were divided into groups by envelope method,with 30 patients in each group.The control group was treated with single Metformin while the standardized use of coronary heart disease drugs.The observation group was treated with Liraglutide combined with Metformin,and the efficacy was compared.Results Compared to the control group,the patients in the observation group had significant advantages in blood glucose levels,cardiac function index levels,incidence of adverse drug reactions,and quality of life scores at all time points after treatment,the difference was statistically significant(P<0.05).Conclusion Liraglutide combined with Metformin in diabetes patients with coronary heart disease can significantly improve blood glucose levels and cardiac function;During the medication period,there were no drug-related adverse reactions and the quality of life was significantly improved compared to before treatment.